{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Incannex Healthcare Inc."},"Symbol":{"label":"Symbol","value":"IXHL"},"Address":{"label":"Address","value":"525 COLLIBS STREET,LEVEL 39, RIALTO SOUTH TOWER, NORWEST, 3000, Australia"},"Phone":{"label":"Phone","value":"+61 425703805"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Australia and South Pacific"},"CompanyDescription":{"label":"Company Description","value":"Incannex Healthcare Ltd is developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products."},"CompanyUrl":{"label":"Company Url","value":"https://www.incannex.com.au"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Joel Latham","title":"President, Chief Executive Officer & Director"},{"name":"Lekhram Changoer","title":"Chief Technology Officer"},{"name":"Luigi M. Barbato","title":"Chief Medical Officer"},{"name":"Mark Bleackley","title":"Chief Scientific Officer"},{"name":"Parisa Asvadi","title":"Vice President-Research & Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}